


02-14-02

W. Sector H
Box 5-182
DMS
5-1-02



Docket Number 4-31193A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EF 024119910 US
Express Mail Label Number

February 14, 2002
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1653

PIPPIG ET AL.

APPLICATION NO: 09/817,487

FILED: MARCH 26, 2001

FOR: SELECTABLE MARKER GENES

Attention: Box Missing Parts

Assistant Commissioner for Patents
Washington, DC 20231

TRANSMITTAL LETTER

Sir:

Enclosed please find the following:

1. Original and one copy of Response to Notice to File Missing Parts of Nonprovisional Application;
2. Copy of Notice to File Missing Parts of Nonprovisional Application;
3. Declaration and Power of Attorney for U.S. Patent Applications signed by all inventors;
4. Submission of Sequence Listing Including Statement of Verification and diskette containing sequence listing in computer readable form; and
5. Return postcard.

Respectfully submitted,

Thomas Savitsky
Attorney for Applicants
Reg. No. 31,661
(908) 522-6765

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Date: February 14, 2002



Docket Number 4-31193A

FILED BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EF 024119910 US
Express Mail Label Number

February 14, 2002
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1653

PIPPIG ET AL.

APPLICATION NO: 09/817,487

FILED: MARCH 26, 2001

FOR: SELECTABLE MARKER GENES

Attention: Box Missing Parts
Assistant Commissioner for Patents
Washington, DC 20231

RESPONSE TO NOTICE TO FILE MISSING PARTS

Sir:

The Notice to File Missing Parts of Application, dated January 7, 2002 (a copy of which is enclosed), has a shortened statutory time set to expire on March 7, 2002.

In response, applicants now submit an original or copy of a fully executed Declaration and Power of Attorney. Please charge the \$130 surcharge fee under 37 CFR §1.16(e) to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Applicants also submit a diskette containing the sequence listing in computer readable form, together with a paper copy of same and a statement of verification that the contents of the diskette and paper copy are the same.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation. A duplicate copy of this letter is provided for charging purposes.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Date: February 14, 2002

Thomas Savitsky
Thomas Savitsky
Attorney for Applicants
Reg. No. 31,661
(908) 522-6765

#6



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/817,487	03/26/2001	Susanne Dagmar Pippig	4-31193A

001095
THOMAS HOXIE
NOVARTIS CORPORATION
PATENT AND TRADEMARK DEPT
564 MORRIS AVENUE
SUMMIT, NJ 079011027



CONFIRMATION NO. 9170

FORMALITIES LETTER



OC000000007272257

Date Mailed: 01/07/2002

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

02/21/2002 EAREGAY1 00000092 190134 09817487

01 FC:105

130.00 CH

*A copy of this notice **MUST** be returned with the reply.*

M
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE